Andra språk GSK plc

Aktier

GSK

GB00BN7SWP63

Farmaceutiska produkter

Marknaden stängd - London S.E. Andra börsplatser 17.35.14 2026-07-17			5-dagars förändring	Förändring 1 jan.
1 916,50 ^GBX	−2,02 %		−2,19 %	+5,04 %

18.37	Brittiska FTSE 100 stiger efter lyft för kraftbolag och energi; Burnham ny ledare för Labour	RE
16.58	Europeiska ADR-noteringar backar i USA-handeln på fredagen	MT

Andra språk

18.37	UK's FTSE 100 rises on utilities, energy boost; Burnham becomes Labour Party leader
18.10	Schwach - Erneute Abgaben im Technologie-Sektor
16.58	European Equities Traded in the US as American Depositary Receipts Decline Friday
16.26	Global markets live: Netflix, Coca-Cola, Apple, Google, SpaceX…
15.49	WOCHENVORSCHAU/27. Juli bis 1. August (31. KW)
15.23	Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday as Investors Retreat From Chipmaker Stocks
15.07	GSK Shares Slide After Drugmaker Drops Chronic Cough Treatment
14.34	Jefferies belässt GSK auf 'Buy' - Ziel 2500 Pence
13.47	Schwach - Abverkauf im Technologie-Sektor geht weiter
13.44	GSK stellt Entwicklung von Medikament gegen chronischen Husten ein
13.11	FTSE 100 bucks European AI stock selloff
13.03	UK's FTSE 100 flat as energy gains offset banks; Burnham set to become prime minister
12.23	GSK Stops Camlipixant Program in Refractory Chronic Cough After Phase 3 Data
12.18	GSK Ends Camlipixant Program for Chronic Cough on Limited Efficacy
12.06	Aktien Europa: Schwache Halbleiterwerte und Inflationssorgen belasten
11.56	GSK ends camlipixant research in RCC as trials show "limited efficacy"
11.43	WINNERS & LOSERS: Vega ups Vodafone stake; GSK drug trial disappoints
11.36	Gsk plc Provides Update on Calm-1 and Calm-2 Phase III Trials for Camlipixant in Refractory Chronic Cough
11.04	GSK Stops Development of Drug Candidate for Chronic Cough
10.42	GSK stops development of chronic cough drug after late-stage trial miss
10.36	GSK : provides an update on CALM-1 and CALM-2 phase III trials for camlipixant in refractory chronic cough (RCC)
07-16	India's Serum Institute partners with Gates MRI to make experimental TB vaccine
07-15	GSK Completes $10.6 Billion Acquisition of Nuvalent
07-15	What If A Shingles Jab Could Also Protect Your Brain?
07-15	GSK completes USD10.6 billion acquisition of Nuvalent